Waldencast (NASDAQ:WALD) Price Target Raised to $7.25 at DA Davidson

Waldencast (NASDAQ:WALD) had its price target boosted by DA Davidson from $6.50 to $7.25 in a research report released on Wednesday, Benzinga reports. DA Davidson currently has a buy rating on the stock.

Separately, Telsey Advisory Group reduced their price objective on Waldencast from $8.00 to $6.00 and set an outperform rating for the company in a research report on Thursday, August 29th.

Waldencast Stock Performance

WALD stock opened at $3.52 on Wednesday. Waldencast has a twelve month low of $2.40 and a twelve month high of $12.00. The company has a quick ratio of 0.82, a current ratio of 1.47 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average of $3.16 and a 200 day moving average of $4.65.

Institutional Trading of Waldencast

Institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP bought a new stake in shares of Waldencast in the 2nd quarter worth $37,000. Catalina Capital Group LLC bought a new stake in shares of Waldencast in the 1st quarter worth $73,000. Cubist Systematic Strategies LLC bought a new stake in shares of Waldencast in the second quarter worth $85,000. Norden Group LLC bought a new stake in shares of Waldencast in the first quarter worth $92,000. Finally, Simplicity Wealth LLC bought a new stake in shares of Waldencast in the first quarter worth $142,000. Institutional investors own 41.97% of the company’s stock.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.